Scientific Programme

Friday, 20 January 2017

08.30 - 08.40 Welcome
M. Brausi, Modena (IT)
P. Gontero, Turin (IT)
J. Palou, Barcelona (ES)

08.40 - 09.00 Opening address
Epigenetics in urogenital cancer
M. Esteller, Barcelona (ES)

09.00 - 13.15 Prostate cancer I: Diagnosis, pathology and active surveillance
Chairs: M. Brausi, Modena (IT)
A. Heidenreich, Cologne (DE)

09.00 - 10.00 What is an acceptable standard for prostate biopsy in 2017?

09.00 - 09.15 How to get the best information from a non MRI guided prostate biopsy
B. Djavan, Vienna (AT)

09.15 - 09.30 Selecting patients for biopsy in the era of MRI
J. Barentsz, Nijmegen (NL)

09.30 - 09.45 Targeted MRI prostate biopsy: Relevant drawbacks
A. Briganti, Milan (IT)

09.45 - 10.00 Discussion

10.00 - 10.15 Role of genomic markers in the diagnostic pathway and prognosis of prostate cancer: Ready for prime?
C. Evans, Sacramento (US)

10.15 - 10.20 Discussion

10.20 - 10.35 A new prostate cancer grading system: A validated alternative to the Gleason Score: Is there a consensus among pathologists?
F. Algaba, Barcelona (ES)

10.35 - 10.40 Discussion

10.40 - 10.55 How to avoid significant cancers when considering active surveillance
J. Hugosson, Gothenburg (SE)

10.55 - 11.00 Discussion
11.00 – 11.20  Refreshment break

11.20 – 11.35  Active surveillance: Which protocol?
A. Alberts, Rotterdam (NL)

11.35 – 11.50  Focal therapy (Video)
S. Crouzet, Lyon (FR)

11.50 – 12.05  Partial radical prostatectomy (Video)
A. Villers, Lille (FR)

12.05 – 12.20  Novel radiotherapy approaches
A. Bossi, Villejuif (FR)

12.20 – 12.30  Discussion

11.20 – 12.30  DEBATE: Conservative treatments for intermediate risk patients: Which alternatives?
Chairs:  J. Hugosson, Gothenburg (SE)
         H. Huland, Hamburg (DE)

11.20 – 11.35  Active surveillance: Which protocol?
A. Alberts, Rotterdam (NL)

11.35 – 11.50  Focal therapy (Video)
S. Crouzet, Lyon (FR)

11.50 – 12.05  Partial radical prostatectomy (Video)
A. Villers, Lille (FR)

12.05 – 12.20  Novel radiotherapy approaches
A. Bossi, Villejuif (FR)

12.20 – 12.30  Discussion

12.30 – 13.05  Active treatment of low risk prostate cancer

12.30 – 12.40  Definition of low and very low risk PCa in 2017
M. Sedelaar, Nijmegen (NL)

12.40 – 13.05  DEBATE: In low-risk patients radical prostatectomy, even minimally invasive, should be abandoned

12.40 – 12.50  Pro
A. Heidenreich, Cologne (DE)

12.50 – 13.00  Con
H. Huland, Hamburg (DE)

13.00 – 13.05  Discussion

13.05 – 14.00  Lunch

14.00 – 17.45  Renal cancer I: Localised
Chairs:  E. Linares, Madrid (ES)
         P. Mulders, Nijmegen (NL)

14.00 – 14.15  Novel imaging modalities for the solid renal mass
J. Walz, Marseille (FR)

14.15 – 14.20  Discussion

14.20 – 14.35  ESUR Lecture: Prognostic and predictive biomarkers and tumour heterogeneity in renal cell carcinoma
K. Junker, Homburg (DE)

14.35 – 14.40  Discussion

14.40 – 15.15  DEBATE: Renal biopsy for small renal masses: Always?
14.40 – 14.50  Yes  
A. Volpe, Novara (IT)

14.50 – 15.00  No  
H. Langenhuijsen, Nijmegen (NL)

15.00 – 15.15  Questions and clinical cases to debaters

15.15 – 16.15  Renal surgery  
Chairs: E. Liatsikos, Patras (GR)  
A. Mottrie, Aalst (BE)

15.15 – 15.30  New anatomical considerations in planning renal surgery  
V. Ficarra, Udine (IT)

15.30 – 15.35  Discussion

15.35 – 16.05  DEBATE: The importance of ischemia vs volume of parenchyma during partial nephrectomy

15.35 – 15.50  Ischemia (Video)  
G. Janetschek, Vienna (AT)

15.50 – 16.05  Volume of preserved parenchyma (Video)  
A. Minervini, Florence (IT)

16.05 – 16.15  Questions and clinical cases to the debaters

16.15 – 16.45  Clinical cases: Partial nephrectomy: Targeting the best approach for the best patients  
Chair: P. Gontero, Turin (IT)

Panelists:  
A. Minervini, Florence (IT)  
P. Mulders, Nijmegen (NL)  
J. Pena, Barcelona (ES)  
H. Van Poppel, Leuven (BE)  
A. Volpe, Novara (IT)

16.45 – 17.00  Refreshment break

17.00 – 17.45  DEBATE: Alternative treatments of small renal masses in the elderly (≥75 years) with co-morbid conditions  
Chairs: A. Govorov, Moscow (RU)  
A. Volpe, Novara (IT)

17.00 – 17.10  Focal therapy (Video)  
P. Laguna, Amsterdam (NL)

17.10 – 17.30  Surgery (minimally invasive: R/LAP) (Video)  
F. Gaboardi, Milan (IT)  
A. Mottrie, Aalst (BE)

17.30 – 17.40  Mini-Open: Still room? (Video)  
M. Brausi, Modena (IT)

17.40 – 17.45  Discussion
17.45 – 18.45 Urothelial and bladder cancer I
Chairs: W. Artibani, Verona (IT)
G. Thalmann, Berne (CH)

17.45 – 17.55 Recovery enhancement programmes for radical cystectomy
M. Colombel, Lyon (FR)

17.55 – 18.05 How to prevent and reduce the complication rate in patients eligible for radical cystectomy?
M. Rink, Hamburg (DE)

18.05 – 18.10 Discussion

18.10 – 18.45 DEBATE: Radical cystectomy vs bladder sparing modalities in the elderly (≥75 years)

18.10 – 18.20 Radical cystectomy
A. Stenzl, Tubingen (DE)

18.20 – 18.30 Bladder sparing modalities
R. Huddart, Sutton (GB)

18.30 – 18.45 Questions to debaters and clinical cases
W. Artibani, Verona (IT)
Saturday, 21 January 2017

08.30 – 10.30  Prostate cancer II: Diagnosis and locally advanced
    Chairs: N. Clarke, Manchester (GB)
            F. Montorsi, Milan (IT)

08.30 – 08.45  Ideal anatomical extent of lymphadenectomy
    P. Sooriakumaran, London (GB)

08.45 – 09.00  Novel diagnostic tools for lymph node staging
    M. Graefen, Hamburg (DE)

09.00 – 09.55  Extended lymphadenectomy in high risk prostate cancer: Different approaches

09.00 – 09.15  Open approach (Video)
    S. Joniau, Leuven (BE)

09.15 – 09.30  Laparoscopic approach (Video)
    J. Rassweiler, Heilbronn (DE)

09.30 – 09.45  Robotic approach (Video)
    H. Van Der Poel, Amsterdam (NL)

09.45 – 09.55  Discussion

09.55 – 10.10  Pathological evaluation of lymph nodes: What urologists should know from pathologists
    and vice versa
    F. Algaba, Barcelona (ES)

10.10 – 10.15  Discussion

10.15 – 10.25  Adjuvant treatment in node positive patients with undetectable PSA
    N. Clarke, Manchester (GB)

10.25 – 10.30  Discussion

10.30 – 11.30  Testis and penile cancer
    Chairs: P. Chlosta, Cracow (PL)
            J. Rubio, Valencia (ES)

10.30 – 10.45  How to avoid sub-optimal treatment outcomes in testicular cancer
    A. Heidenreich, Cologne (DE)

10.45 – 10.50  Discussion

10.50 – 11.05  Lymph node staging in penile cancer: When and how
    C. Protzel, Rostock (DE)

11.05 – 11.20  Robotic inguinal lymph node dissection in penile cancer
    V. Sangar, Manchester (GB)

11.20 – 11.30  Discussion

11.30 – 12.00  Refreshment break
12.00 – 13.45  Urothelial cancer II: Challenges in muscle invasive and non-muscle invasive bladder cancer
Chairs: M. Colombel, Lyon (FR)
J. Palou, Barcelona (ES)

12.00 – 12.15  Unusual metastatic sites after minimally invasive radical cystectomy: Myth or reality?
R. Van Velthoven, Brussels (BE)

12.15 – 12.20  Discussion

12.20 – 12.35  Salvage radical cystectomy after radiotherapy: A more complicated procedure?
P. Gontero, Turin (IT)

12.35 – 12.40  Discussion

12.40 – 13.00  DEBATE: BCG as the standard treatment of T1 HG TCC of the bladder: Still true?

12.40 – 12.50  Yes
M. Babjuk, Prague (CZ)

12.50 – 13.00  No
M. Brausi, Modena (IT)

13.00 – 13.30  Challenges in NMIBC: Case presentation
Chair: J. Palou, Barcelona (ES)
Panelists: M. Babjuk, Prague (CZ)
M. Brausi, Modena (IT)
A. Masson-Lecomte, Creteil (FR)
M. Oderda, Turin (IT)
E. Xylinas, Paris (FR)

13.30 – 13.45  Up-date in the diagnosis and treatment of upper urinary tract transitional cell carcinoma (UUT TCC)
M. Rouprêt, Paris (FR)

14.30 – 16.45  STEPS (Session To Evaluate ProgresS) programme
Closed programme: participation by invitation only

Led by Prof. M. Brausi, Modena (IT)

Prostate Cancer table: Chair: C. Evans, Sacramento (US)  ESOU: S. Joniau, Leuven (BE)
Bladder Cancer table: Chair: R. Hautmann, Neu-Ulm (DE)  ESOU: M. Colombel, Lyon (FR)
Renal Cancer table: Chair: P. Mulders, Nijmegen (NL)  ESOU: P. Chlosta, Cracow (PL)
Testis Cancer table: Chair: A. Heidenreich, Cologne (DE)  ESOU: M. Sedelaar, Nijmegen (NL)
Radical cystectomy is one of the most complicated surgeries in urology. The correct management at all the different steps is the key for success and to avoid or at least decrease postoperative complications. We will review the different steps and main problems to deal with when deciding, doing or controlling a patient after cystectomy. We will focus on practical aspects that will help urologists and their patients that have to undergo this radical surgery.

**14.30 European School of Urology: a unique possibility for urological education**

**14.35 Open discussion on Preoperative priorities**
- Nutrition preop
- Bowel preparation
- Anemia
- Location of the stoma
- Renal function
- Medication including prophylaxis

**15.25 Intraoperative**
- Rectal injury
- Vascular injury
- Urethral margin
- Ureteral margins
- Nerve sparing
- Stenting?
- Which diversion and when

**16.15 Refreshment break**

**16.35 Postoperative**
- Fever
- Ileus: basic steps
- Urine leak
- Bowel leak
- Wound dehiscence
- When to remove stents
- Antibiotics

Follow-up of the incontinent diversion
Follow-up of the neobladder

**17.30 Close**
Sunday, 22 January 2017

09.00 – 10.00 Renal cancer II: Locally advanced and metastatic
Chairs: M. De Santis, Coventry (GB)
       H. Van Poppel, Leuven (BE)

09.00 – 09.15 Cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era
O. Rodriguez Faba, Barcelona (ES)

09.15 – 09.20 Discussion

09.20 – 09.35 Disasters in renal cancer surgery: How to avoid them (Video)
V. Pansadoro, Rome (IT)

09.35 – 09.40 Discussion

09.40 – 09.55 The role of medical treatment of locally advanced renal cancer
P. Mulders, Nijmegen (NL)

09.55 – 10.00 Discussion

10.00 – 11.10 The best of uro-oncology in 2016
Chairs: V. Ficarra, Udine (IT)
       M. Sedelaar, Nijmegen (NL)

10.00 – 10.15 Kidney cancer
U. Capitanio, Milan (IT)

10.15 – 10.30 Bladder cancer
A. Noon, Sheffield (GB)

10.30 – 10.45 Testis cancer
M. Salagierski, Zielona Góra (PL)

10.45 – 11.00 Prostate cancer
R. Van Den Bergh, Amsterdam (NL)

11.00 – 11.10 Discussion

11.10 – 11.30 Refreshment break

11.30 – 12.50 Prostate and bladder cancer III: Advanced and metastatic
Chairs: B. Djavan, Vienna (AT)
       C. Evans, Sacramento (US)

11.30 – 11.45 Checkpoint inhibitors in bladder cancer
G. Thalmann, Berne (CH)

11.45 – 11.50 Discussion

11.50 – 12.05 Robotic salvage retroperitoneal lymph node dissection for patients with an elevated PSA after radical prostatectomy (Video)
F. Montorsi, Milan (IT)

12.05 – 12.10 Discussion
12.10 - 12.25 Radical prostatectomy in oligo metastatic disease (Video)
S. Joniau, Leuven (BE)

12.25 - 12.30 Discussion

12.30 - 12.45 Which men with primary metastatic prostate cancer should have cytotoxic agents upfront?
M. De Santis, Coventry (GB)

12.45 - 12.50 Discussion

12.50 - 13.00 Announcement of ESOU Achievement Award

13.00 - 13.10 Closing remarks
M. Brausi, Modena (IT)
P. Gontero, Turin (IT)
J. Palou, Barcelona (ES)